APOE and Alzheimer disease: To prevent this, providers should perform APOE ε4 testing on patients before starting treatment with donanemab, as patients who are APOE ε4 homozygotes—about 15% of AD patients—are at a higher risk of developing ARIA, including symptomatic, serious, and severe radiographic ARIA, compared to heterozygotes and non-carriers [44].